Quick Takeaways
- VNDA - Vanda Pharmaceuticals Inc. financial facts are built from SEC company filings data.
- Latest metrics period on this page: Q4 2025.
- Headline metric: Return On Equity -51%.
Professional SEC-based dashboard for profitability, financial health, and growth with transparent scoring logic. Latest period: Q4 2025.
Facts and ratios are grounded in SEC company facts linked to the latest 10-Q/10-K cycle.
See Original FilingLatest SEC snapshot (2026-02-05) highlights Return On Equity -50.9%, Return On Assets -16.5%, and Operating Margin -70.5%.
Transparent 0-100 scoring model based on profitability, financial health, and growth factors.
39.7/100
Weak Confidence high
-51%
Metric score 0.0/100
-17%
Metric score 0.0/100
Current Ratio and Debt-to-equity
Return On Equity, Return On Assets, and Operating Margin
Return On Equity
-51%
YoY: +1360%
Industry median: -43% (n=675)
Return On Assets
-17%
YoY: +1229%
Industry median: -47% (n=673)
Operating Margin
-71%
YoY: +242%
Industry median: -121% (n=298)
Current Ratio
2.39x
YoY: -46%
Industry median: 3.39x (n=667)
Quick Ratio
2.19x
YoY: -36%
Industry median: 1.51x (n=289)
Debt-to-equity
0.04x
YoY: +53%
Industry median: 0.26x (n=530)
Revenues YoY
8.7%
YoY:
Industry median: 7.3% (n=302)
NetIncomeLoss YoY
-1067%
YoY:
Industry median: -0.93% (n=641)
| Metric | Latest value | YoY change |
|---|---|---|
| Return On Equity | -51% | +1360% |
| Return On Assets | -16% | +1229% |
| Operating Margin | -71% | +242% |
| Metric | Latest value | YoY change |
|---|---|---|
| Current Ratio | 2.39x | -46% |
| Quick Ratio | 2.19x | -36% |
| Debt-to-equity | 0.04x | +53% |
| Metric | Latest value | YoY change |
|---|---|---|
| Revenues YoY | 8.7% | |
| NetIncomeLoss YoY | -1067% |
| Metric | Latest value | YoY change |
|---|---|---|
| Entity Common Stock, Shares Outstanding | 59,108,030 | +1.4% |
| Common Stock, Shares, Outstanding | 59,101,630 | +1.4% |
| Common Stock, Value, Issued | $59,000 | +1.7% |
| Weighted Average Number of Shares Outstanding, Basic | 58,930,157 | +1.3% |
| Weighted Average Number of Shares Outstanding, Diluted | 58,930,157 | +1.3% |
This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.
| Metric | Weight | V1 threshold |
|---|---|---|
| ROIC | 20 | 5% to 20% |
| ROE | 15 | 8% to 25% |
| ROA | 10 | 2% to 10% |
| Operating Margin | 5 | 5% to 25% |
| Current Ratio | 12 | 1.0x to 2.0x |
| Quick Ratio | 8 | 0.8x to 1.5x |
| Debt to Equity | 10 | 0.3x to 2.0x (lower is better) |
| Revenue YoY | 10 | -10% to +20% |
| Net Income YoY | 10 | -10% to +20% |
Metrics are computed with a market-consensus convention designed for cross-portal comparability.